AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

A Multicenter, Randomized, Double-Blind, 12-Week Study Of The Safety And Efficacy Of AN2728 Versus AN2728 Vehicle In The Treatment Of Patients With Mild-To-Moderate Plaque-Type Psoriasis

The purpose of this study is to determine whether AN2728 topical ointment is a safe and effective treatment for mild-to-moderate plaque-type psoriasis.

Inclusion Criteria:

• Clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of total body surface area (BSA) excluding face, scalp, and genitals
• Willingness and ability to apply study medication as directed, comply with study instructions, and commit to attending all study visits
• Women of childbearing potential must agree to use contraception for the entire study period

Exclusion Criteria:

• Any dermatological conditions that could interfere with clinical evaluations
• Concurrent or recent use of certain topical or systemic medications without a sufficient washout period
• Significant confounding conditions as assessed by study doctor
• Participated in any other trial of an investigational drug within 30 days or participation in a research study concurrent with this study
• Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
• Use of a beta-blocking medication (e.g., propranolol) if the dose has not been stabilized for at least 3 months
• Pregnancy or lactation